Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Status: Enrolling
Updated:  3/8/2018
Children' Hospital Boston
mi
from
Boston, MA
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Status: Enrolling
Updated: 3/8/2018
Children' Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Status: Enrolling
Updated:  3/8/2018
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Status: Enrolling
Updated: 3/8/2018
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Status: Enrolling
Updated:  3/8/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Status: Enrolling
Updated: 3/8/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Status: Enrolling
Updated:  3/8/2018
Childrens Medical Center - Univ. of Texas SW Medical Center
mi
from
Dallas, TX
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Status: Enrolling
Updated: 3/8/2018
Childrens Medical Center - Univ. of Texas SW Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Status: Enrolling
Updated:  3/8/2018
University of Utah
mi
from
Salt Lake City, UT
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Status: Enrolling
Updated: 3/8/2018
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Status: Enrolling
Updated:  3/8/2018
Children's Hospital at Westmead
mi
from
Westmead,
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Status: Enrolling
Updated: 3/8/2018
Children's Hospital at Westmead
mi
from
Westmead,
Click here to add this to my saved trials
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Status: Enrolling
Updated:  3/8/2018
NIH
mi
from
Bethesda, MD
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Status: Enrolling
Updated: 3/8/2018
NIH
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Status: Enrolling
Updated:  3/8/2018
Washington University in St. Louis
mi
from
Saint Louis, MO
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Status: Enrolling
Updated: 3/8/2018
Washington University in St. Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Status: Enrolling
Updated:  3/8/2018
Childrens National Medical Center
mi
from
Washington,
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Status: Enrolling
Updated: 3/8/2018
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Testosterone for Treating Cachexia in Patients With Squamous Cell Carcinoma
Nutrition and Anabolic Interventions in Squamous Cell Carcinoma
Status: Enrolling
Updated:  3/8/2018
University of Texas Medical Branch
mi
from
Galveston, TX
Testosterone for Treating Cachexia in Patients With Squamous Cell Carcinoma
Nutrition and Anabolic Interventions in Squamous Cell Carcinoma
Status: Enrolling
Updated: 3/8/2018
University of Texas Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer
A Multicenter, Open-Label, Phase II Study of LE-DT for Efficacy and Safety in Patients With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  3/8/2018
Georgetown University Medical Center
mi
from
Washington,
Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer
A Multicenter, Open-Label, Phase II Study of LE-DT for Efficacy and Safety in Patients With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 3/8/2018
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer
A Multicenter, Open-Label, Phase II Study of LE-DT for Efficacy and Safety in Patients With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  3/8/2018
Providence Portland Medical Center
mi
from
Portland, OR
Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer
A Multicenter, Open-Label, Phase II Study of LE-DT for Efficacy and Safety in Patients With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 3/8/2018
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Adaptation of the American Cancer Society (ACS) Early Detection of Prostate Cancer Patient Decision Aid for Spanish Speaking Men
Adaptation of the American Cancer Society (ACS) Early Detection of Prostate Cancer Patient Decision Aid for Spanish Speaking Men
Status: Enrolling
Updated:  3/8/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Adaptation of the American Cancer Society (ACS) Early Detection of Prostate Cancer Patient Decision Aid for Spanish Speaking Men
Adaptation of the American Cancer Society (ACS) Early Detection of Prostate Cancer Patient Decision Aid for Spanish Speaking Men
Status: Enrolling
Updated: 3/8/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
A Genotype-guided Dosing Study of mFOLFIRINOX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated:  3/8/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
A Genotype-guided Dosing Study of mFOLFIRINOX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated: 3/8/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
A Genotype-guided Dosing Study of mFOLFIRINOX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated:  3/8/2018
Evanston CCOP-NorthShore University HealthSystem
mi
from
Evanston, IL
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
A Genotype-guided Dosing Study of mFOLFIRINOX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Enrolling
Updated: 3/8/2018
Evanston CCOP-NorthShore University HealthSystem
mi
from
Evanston, IL
Click here to add this to my saved trials
Photoacoustic Imaging of the Ovary
Photoacoustic Imaging of the Ovary
Status: Enrolling
Updated:  3/8/2018
UConn Health
mi
from
Farmington, CT
Photoacoustic Imaging of the Ovary
Photoacoustic Imaging of the Ovary
Status: Enrolling
Updated: 3/8/2018
UConn Health
mi
from
Farmington, CT
Click here to add this to my saved trials
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  3/8/2018
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 3/8/2018
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  3/8/2018
Indiana University Health Melvin And Bren Simon Cancer Center
mi
from
Indianapolis, IN
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 3/8/2018
Indiana University Health Melvin And Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  3/8/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 3/8/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  3/8/2018
San Juan Oncology
mi
from
Farmington, NM
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 3/8/2018
San Juan Oncology
mi
from
Farmington, NM
Click here to add this to my saved trials
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  3/8/2018
Laura and Isaac Perlmutter Cancer Center @ NYU Langone
mi
from
New York, NY
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 3/8/2018
Laura and Isaac Perlmutter Cancer Center @ NYU Langone
mi
from
New York, NY
Click here to add this to my saved trials
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  3/8/2018
Sarah Cannon Research Institute
mi
from
Nashville, TN
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 3/8/2018
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Beverly Hills, CA
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Burbank, CA
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Burbank, CA
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Research Site 2
mi
from
Los Angeles, CA
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Research Site 2
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Montebello, CA
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Montebello, CA
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Orange, CA
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
San Diego, CA
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Boca Raton, FL
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Honolulu, HI
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Honolulu, HI
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Evanston, IL
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Evanston, IL
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Bethesda, MD
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Bethesda, MD
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Boston, MA
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Lebanon, NH
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Lebanon, NH
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Charlotte, NC
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Washington, WA
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Washington, WA
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
mi
from
Darlinghurst,
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
mi
from
Darlinghurst,
Click here to add this to my saved trials
Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
High-Dose Infusional Taxol, Amifostine, Doxorubicin, and Cyclophosphamide Followed by Stem Cell Rescue for High Risk Primary and Responsive Metastatic Breast Cancer
Status: Enrolling
Updated:  3/8/2018
Cancer Center and Beckman Research Institute, City of Hope
mi
from
Duarte, CA
Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
High-Dose Infusional Taxol, Amifostine, Doxorubicin, and Cyclophosphamide Followed by Stem Cell Rescue for High Risk Primary and Responsive Metastatic Breast Cancer
Status: Enrolling
Updated: 3/8/2018
Cancer Center and Beckman Research Institute, City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas
Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas
Status: Enrolling
Updated:  3/9/2018
Southeastern Gynecologic Oncology
mi
from
Atlanta, GA
Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas
Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas
Status: Enrolling
Updated: 3/9/2018
Southeastern Gynecologic Oncology
mi
from
Atlanta, GA
Click here to add this to my saved trials
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 Year Adjuvant Imatinib Mesylate (Gleevec®) in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)
Status: Enrolling
Updated:  3/9/2018
University of Colorado Univ Colorado
mi
from
Aurora, CO
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 Year Adjuvant Imatinib Mesylate (Gleevec®) in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)
Status: Enrolling
Updated: 3/9/2018
University of Colorado Univ Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 Year Adjuvant Imatinib Mesylate (Gleevec®) in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)
Status: Enrolling
Updated:  3/9/2018
Washington Hospital Center Department of Medical Oncology
mi
from
Washington,
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 Year Adjuvant Imatinib Mesylate (Gleevec®) in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)
Status: Enrolling
Updated: 3/9/2018
Washington Hospital Center Department of Medical Oncology
mi
from
Washington,
Click here to add this to my saved trials
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 Year Adjuvant Imatinib Mesylate (Gleevec®) in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)
Status: Enrolling
Updated:  3/9/2018
Longstreet Cancer Center
mi
from
Gainesville, GA
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 Year Adjuvant Imatinib Mesylate (Gleevec®) in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)
Status: Enrolling
Updated: 3/9/2018
Longstreet Cancer Center
mi
from
Gainesville, GA
Click here to add this to my saved trials
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 Year Adjuvant Imatinib Mesylate (Gleevec®) in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)
Status: Enrolling
Updated:  3/9/2018
Southern Nevada Cancer Research Foundation S. Nevada Cancer Res (2)
mi
from
Las Vegas, NV
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 Year Adjuvant Imatinib Mesylate (Gleevec®) in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)
Status: Enrolling
Updated: 3/9/2018
Southern Nevada Cancer Research Foundation S. Nevada Cancer Res (2)
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 Year Adjuvant Imatinib Mesylate (Gleevec®) in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)
Status: Enrolling
Updated:  3/9/2018
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 Year Adjuvant Imatinib Mesylate (Gleevec®) in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)
Status: Enrolling
Updated: 3/9/2018
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 Year Adjuvant Imatinib Mesylate (Gleevec®) in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)
Status: Enrolling
Updated:  3/9/2018
Oregon Health & Science University OHS University
mi
from
Portland, OR
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 Year Adjuvant Imatinib Mesylate (Gleevec®) in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)
Status: Enrolling
Updated: 3/9/2018
Oregon Health & Science University OHS University
mi
from
Portland, OR
Click here to add this to my saved trials
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 Year Adjuvant Imatinib Mesylate (Gleevec®) in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)
Status: Enrolling
Updated:  3/9/2018
Penn State University / Milton S. Hershey Medical Center Penn Stat University
mi
from
Hershey, PA
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 Year Adjuvant Imatinib Mesylate (Gleevec®) in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)
Status: Enrolling
Updated: 3/9/2018
Penn State University / Milton S. Hershey Medical Center Penn Stat University
mi
from
Hershey, PA
Click here to add this to my saved trials
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 Year Adjuvant Imatinib Mesylate (Gleevec®) in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)
Status: Enrolling
Updated:  3/9/2018
Roger Williams Medical Center Medical Center
mi
from
Providence, RI
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 Year Adjuvant Imatinib Mesylate (Gleevec®) in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)
Status: Enrolling
Updated: 3/9/2018
Roger Williams Medical Center Medical Center
mi
from
Providence, RI
Click here to add this to my saved trials
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 Year Adjuvant Imatinib Mesylate (Gleevec®) in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)
Status: Enrolling
Updated:  3/9/2018
Kingport Hematology Oncology
mi
from
Kingsport, TN
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 Year Adjuvant Imatinib Mesylate (Gleevec®) in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)
Status: Enrolling
Updated: 3/9/2018
Kingport Hematology Oncology
mi
from
Kingsport, TN
Click here to add this to my saved trials
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 Year Adjuvant Imatinib Mesylate (Gleevec®) in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)
Status: Enrolling
Updated:  3/9/2018
South Texas Oncology and Hematology, PA South Texas Onc/Hem
mi
from
San Antonio, TX
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
A Phase II, Non-Randomized, Open-Label Multicenter Study of 5 Year Adjuvant Imatinib Mesylate (Gleevec®) in Patients at Significant Risk for Recurrence Following Complete Resection of Primary Gastrointestinal Stromal Tumor (GIST)
Status: Enrolling
Updated: 3/9/2018
South Texas Oncology and Hematology, PA South Texas Onc/Hem
mi
from
San Antonio, TX
Click here to add this to my saved trials